Clinical Trial Update: Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating a combination of farletuzumab, carboplatin, and pegylated liposomal doxorubicin for platinum-sensitive epithelial ovarian cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Farletuzumab (farletuzumab)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Morphotek | Conditions: Epithelial Ovarian Cancer | Phase 1 | Status: COMPLETED